Pennant group chief clinical officer sells $53,699 in stock

Pennant Group, Inc. (NASDAQ:PNTG) Chief Clinical Officer Jason Paul Steik sold 1,394 shares of the company's common stock on August 6, 2026, at a price of $38.522 per share, totaling $53,699. This sale comes as PNTG shares are trading near $39.32, marking a strong 55.66% return over the past year and a 39.68% gain year-to-date. Following the sale, Steik directly holds 15,106 shares of Pennant Group, Inc. common stock.

The information was disclosed in a Form 4 filing with the Securities and Exchange Commission. Analysts note that the stock appears overvalued, trading at a P/E ratio of 42.92. Meanwhile, The Pennant Group reported its second-quarter 2026 financial results, surpassing Wall Street expectations with adjusted earnings of $0.36 per share on revenue of $298.0 million.

This marks a significant revenue increase of 35.8% compared to the same period last year, with adjusted EBITDA rising by 48.2%. In response, Wells Fargo raised its price target for The Pennant Group to $46 from $45, maintaining an Overweight rating.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.